Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous system, conolidine modulates alternate molecular targets. A Science Developments study uncovered that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://thomasf877stk5.blogolenta.com/profile